文献速递物质与行为成瘾

舌下丁丙诺啡-纳洛酮与注射纳曲酮治疗阿片类使用障碍:患者特征指导治疗选择的潜在效用

Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment.
PubMed 文献 · Am J Psychiatry · 2021-06-25

该多中心24周随机对照试验纳入住院阿片类使用障碍患者,比较舌下丁丙诺啡-纳洛酮与缓释注射纳曲酮对复发和起始治疗失败的影响,并检验50项人口学与临床特征作为效应修饰因子。无家可归者使用纳曲酮复发率更低,非无家可归者使用丁丙诺啡-纳洛酮复发率更低;药物偏好、假释/缓刑状态及疼痛与随机化时机影响起始治疗失败。

要点

  • 无家可归患者中纳曲酮组复发率51.6%低于丁丙诺啡-纳洛酮组70.4%(OR=0.45)。
  • 非无家可归患者中纳曲酮组复发率70.9%高于丁丙诺啡-纳洛酮组53.1%(OR=2.15)。
  • 药物偏好、假释/缓刑状态及疼痛与随机化时机与起始治疗失败相关。

核心结论

  • 无家可归、假释/缓刑状态、药物偏好及可能影响耐受性的因素有助于匹配丁丙诺啡或缓释纳曲酮。

研究设计与样本

  • 多中心24周随机比较有效性试验,纳入计划起始药物治疗的住院阿片类使用障碍患者,丁丙诺啡-纳洛酮组N=287,缓释纳曲酮组N=283。
  • 检验50项人口学与临床特征作为药物分配对规律阿片使用复发和起始治疗失败的效应修饰因子,采用逻辑回归并校正多重检验。

主要发现

  • 意向治疗样本中,无家可归者纳曲酮组复发率51.6%低于丁丙诺啡-纳洛酮组70.4%(OR=0.45,95%CI=0.22,0.90)。
  • 非无家可归者纳曲酮组复发率70.9%高于丁丙诺啡-纳洛酮组53.1%(OR=2.15,95%CI=1.44,3.21)。
  • 起始药物亚组中交互作用不显著,无家可归者纳曲酮组复发率41.4%低于丁丙诺啡组68.6%(OR=0.32,95%CI=0.15,0.68),非无家可归者纳曲酮组57.2%与丁丙诺啡组52.0%差异较小(OR=1.24,95%CI=0.80,1.90)。
  • 起始治疗失败的修饰因子包括药物偏好(分配至偏好药物失败更少)、假释/缓刑状态(纳曲酮失败更少)及疼痛与随机化时机(中重度疼痛且早期随机化者纳曲酮失败更多)。

关键数值与推荐

  • 无家可归者分配至缓释纳曲酮相比丁丙诺啡-纳洛酮的复发OR=0.45(95%CI=0.22,0.90)。
  • 非无家可归者分配至缓释纳曲酮相比丁丙诺啡-纳洛酮的复发OR=2.15(95%CI=1.44,3.21)。

临床怎么用

  • 对住院阿片类使用障碍患者,可考虑无家可归状态、假释/缓刑状态、药物偏好及疼痛与随机化时机来个体化选择丁丙诺啡-纳洛酮或缓释纳曲酮。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sublingual buprenorphine-naloxone and extended-release injection naltrexone are effective treatments, with distinct mechanisms, for opioid use disorder. The authors examined whether patients' demographic and clinical characteristics were associated with better response to one medication or the other. METHODS: In a multisite 24-week randomized comparative-effectiveness trial of assignment to buprenorphine-naloxone (N=287) compared with extended-release naltrexone (N=283) comprising inpatients planning to initiate medication treatment for opioid use disorder, 50 demographic and clinical characteristics were examined as moderators of the effect of medication assignment on relapse to regular opioid use and failure to initiate medication. Moderator-by-medication interactions were estimated using logistic regression with correction for multiple testing. RESULTS: In the intent-to-treat sample, patients who reported being homeless had a lower relapse rate if they were assigned to receive extended-release naltrexone (51.6%) compared with buprenorphine-naloxone (70.4%) (odds ratio=0.45, 95% CI=0.22, 0.90); patients who were not homeless had a higher relapse rate if they were assigned to extended-release naltrexone (70.9%) compared with buprenorphine-naloxone (53.1%) (odds ratio=2.15, 95% CI=1.44, 3.21). In the subsample of patients who initiated medication, the interaction was not significant, with a similar pattern of lower relapse with extended-release naltrexone (41.4%) compared with buprenorphine (68.6%) among homeless patients (odds ratio=0.32, 95% CI=0.15, 0.68) but less difference among those not homeless (extended-release naltrexone, 57.2%; buprenorphine, 52.0%; odds ratio=1.24, 95% CI=0.80, 1.90). For failure to initiate medication, moderators were stated preference for medication (failure was less likely if the patient was assigned to the medication preferred), parole and probation status (fewer failures with extended-release naltrexone for those on parole or probation), and presence of pain and timing of randomization (more failure with extended-release naltrexone for patients endorsing moderate to severe pain and randomized early while still undergoing medically managed withdrawal). CONCLUSIONS: Among patients with opioid use disorder admitted to inpatient treatment, homelessness, parole and probation status, medication preference, and factors likely to influence tolerability of medication initiation may be important in matching patients to buprenorphine or extended-release naltrexone.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Nunes EV, Scodes JM, Pavlicova M, et al. Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment. Am J Psychiatry. 2021. PMID: 34170188. doi:10.1176/appi.ajp.2020.20060816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。